Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recommendations about add-on reimbursement for medical devices in France in September 2023

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in September 2023. Twenty recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern, peripheral vascular and neurovascular, neurology and neurosurgery, ENT, spine, ophthalmology, and orthopedic devices, as well as medical aids.

The first step in the assessment is the clinical (actual) benefit (SA), which can be either sufficient or insufficient. This step determines the insertion into the LPPR list. If sufficient, the clinical added value (ASA) is graded on a scale from I (major) to V (absent) for claimed indications, which supports the pricing decisions.

Some examples of the recommendations are provided below.

  • MRI-guided laser thermoablation system VISUALASE by Medtronic (application for registration; sufficient actual benefit; level II of clinical added value compared to craniotomy resection surgery);
  • Liquid embolic agent SQUID by Balt Extrusion (application for registration; sufficient actual benefit; level V of clinical added value compared to ONYX);
  • Paclitaxel-eluting peripheral balloon PASSEO 18 LUX by Biotronik (application for registration; sufficient actual benefit; level V of clinical added value compared to IN.PACT Admiral);
  • Injectable synthetic bone substitute NANOSTIM by Medtronic (application for renewal of registration; sufficient actual benefit; level V of clinical added value compared to synthetic bone substitutes and bone substitutes containing derivatives of animal origin already listed on the LPPR);

Also, recommendations were made in relation to other peripheral vascular devices, ENT, spine, ophthalmology devices, and medical aids.

See the details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.